Pentraxin 3 as a marker of development and severity of stable coronary artery disease
Authors:
- 27 July 2024
- journal article
- research article
- Published by Elsevier in Advances in Medical Sciences
- Vol. 69 (2) , 391-397
Abstract
No abstract availableKeywords
Funding Information
- Uniwersytet Medyczny w Bialymstoku (SUB/1/DN/19/003/1153)
This publication has 30 references indexed in Scilit:
- The potential value of Copeptin and Pentraxin3 for evaluating the severity of coronary stenosis in patients with coronary artery diseaseClinical Biochemistry, 2021
- ESC 2019 guidelines for the diagnosis and management of chronic coronary syndromesHerz, 2020
- Relationship of systemic pentraxin-3 values with coronary plaque components on optical coherence tomography and post-percutaneous coronary intervention outcomes in patients with stable angina pectorisAtherosclerosis, 2020
- The clinical value of inflammatory biomarkers in coronary artery disease: PTX3 as a new inflammatory markerExperimental Gerontology, 2017
- Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general populationNutrition, Metabolism and Cardiovascular Diseases, 2014
- Elevated Levels of Systemic Pentraxin 3 Are Associated With Thin-Cap Fibroatheroma in Coronary Culprit LesionsJACC: Cardiovascular Interventions, 2013
- Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: Data from the Heart and Soul StudyAmerican Heart Journal, 2012
- Novel serum biomarkers in carotid artery stenosis: Useful to identify the vulnerable plaque?Clinical Biochemistry, 2011
- Carotid plaque formation and serum biomarkersAtherosclerosis, 2010
- The Long Pentraxin PTX3: A Modulator of the Immunoinflammatory Response in Atherosclerosis and Cardiovascular DiseasesTrends in Cardiovascular Medicine, 2010